NCT06506955 2026-03-11
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
Clinical Trials
15 trialsNCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT06989437 2026-02-06
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer
Phase 2/3 Recruiting
NCT07321847 2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3 Not yet recruiting
NCT06783140 2025-12-05
PLATINUM-CAN
University Health Network, Toronto
Phase 2/3 Recruiting
NCT03512756 2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc
Phase 2/3 Terminated
NCT01437514 2021-06-07
Effective Study of Preoperative Short-course Radiotherapy for the Advanced Resectable Rectal Cancer
West China Hospital
Phase 2/3 Terminated
NCT03031444 2021-02-01
PARECEC
Peking University Cancer Hospital & Institute
Phase 2/3 Completed
NCT03909724 2020-11-13
SUNRISE-CRC
Amsterdam UMC, location VUmc
Phase 2/3 Unknown
NCT00212615 2020-11-06
XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer
Odense University Hospital
Phase 2/3 Completed
NCT03610100 2019-10-29
ACELARATE
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2/3 Suspended
NCT02208804 2016-11-09
SIM
UMC Utrecht
Phase 2/3 Unknown
NCT00561990 2015-10-15
Nimotuzumab in Adults With Pancreatic Cancer
Oncoscience AG
Phase 2/3 Completed
NCT00561522 2010-07-21
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
Fudan University
Phase 2/3 Unknown
NCT00035334 2006-02-14
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Bellus Health Inc. - a GSK company
Phase 2/3 Completed